https://doi.org/10.1200/jco.23.01569
M
Miso Kim
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
188
Papers
5.0K
Citations
33
h-index
66
i10-index
Miso Kim is an academic researcher from Seoul National University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Lung Cancer Treatments and Mutations & Lung Cancer Research Studies. The author has an h-index of 33, co-authored 160 publications.
ORCID: 0000-0002-4064-4199Papers by this author
worksLenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Journal of Clinical Oncology · 137 citations
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
2024 · Journal of Clinical Oncology · 137 citations
https://doi.org/10.1200/jco.23.01569
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
2023 · Cancer Discovery · 79 citations
https://doi.org/10.1158/2159-8290.cd-23-0964
High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration
2022 · BMC Cancer · 30 citations
https://doi.org/10.1186/s12885-022-10239-6
Diagnosis of secondary peripheral neurolymphomatosis: a multi-center experience
2017 · Leukemia & lymphoma/Leukemia and lymphoma · 15 citations
https://doi.org/10.1080/10428194.2017.1312376
Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy
2022 · Breast Cancer Research and Treatment · 11 citations
https://doi.org/10.1007/s10549-022-06566-8
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat